Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with RCSD1-ABL1-positive acute lymphoblastic leukemia.

Miriam Frech,Lutz B. Jehn,Kathleen Stabla,Stephan Mielke,Björn Steffen,Hermann Einsele,Stephan Metzelder,Andreas Neubauer

HAEMATOLOGICA（2017）

引用 18|浏览28

暂无评分

摘要

The addition of tyrosine kinase inhibitors (TKI) to treatment regimens of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has significantly improved overall survival.160 However, allogeneic stem cell transplantation (allo-SCT) offers the only curative option

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要